CSIMarket
 
Titan Pharmaceuticals Inc   (NASDAQ: TTNP)
Other Ticker:  
 
 
Price: $4.1400 $0.62 17.614%
Day's High: $4.2 Week Perf: 13.74 %
Day's Low: $ 3.42 30 Day Perf: 29.38 %
Volume (M): 277 52 Wk High: $ 14.80
Volume (M$): $ 1,146 52 Wk Avg: $5.45
Open: $3.69 52 Wk Low: $3.03



 Market Capitalization (Millions $) 4
 Shares Outstanding (Millions) 1
 Employees 13
 Revenues (TTM) (Millions $) -
 Net Income (TTM) (Millions $) -6
 Cash Flow (TTM) (Millions $) -5
 Capital Exp. (TTM) (Millions $) 0

Titan Pharmaceuticals Inc
Titan Pharmaceuticals Inc. is a biopharmaceutical company that develops innovative treatments for medical disorders. Based in South San Francisco, California, the company focuses primarily on the development of therapeutics for central nervous system (CNS) disorders and conditions. Titan Pharmaceuticals is known for its expertise in the field of long-term, continuous drug delivery, utilizing its proprietary ProNeura technology platform.

The company has successfully developed and commercialized Probuphine, an implantable buprenorphine-based treatment for opioid addiction. Probuphine is designed to provide a constant, low-level release of medication for six months, eliminating the need for daily dosing and reducing the risk of non-compliance.

In addition to opioid addiction, Titan Pharmaceuticals is actively researching and developing treatments for other CNS disorders, including Parkinson's disease and hypothyroidism. The company has ongoing collaborations with various academic institutions and pharmaceutical partners to advance its research and development pipelines.

Overall, Titan Pharmaceuticals Inc. is dedicated to developing innovative therapies with an emphasis on long-term and continuous drug delivery, aiming to improve patients' quality of life and simplify treatment regimens for various medical conditions.


   Company Address: 10 East 53rd St. New York 10022 NY
   Company Phone Number: 244-4990   Stock Exchange / Ticker: NASDAQ TTNP


   

Stock Performances by Major Competitors

5 Days Decrease / Increase
     
AMGN        0.85% 
EXEL   -2.58%    
BMRN        2.36% 
PODD   -1.09%    
• View Complete Report
   



Stock Market Announcement

Titan Pharmaceuticals Faces Nasdaq Compliance Challenges Amid Strategic Merger

Published Wed, Nov 27 2024 9:06 PM UTC

In a significant development for investors and stakeholders, Titan Pharmaceuticals, Inc. (NASDAQ: TTNP) is navigating turbulent waters with the recent announcement of its non-compliance with Nasdaq?s continued listing requirements. The company received a notice on November 22, 2024, from the Listing Qualifications Department of The Nasdaq Stock Market LLC. This communication...

Merger and Acquisition

Titan Pharmaceuticals to Merge with KE Sdn. Bhd.: A New Strategic Chapter for Biopharmaceuticals

Published Mon, Aug 19 2024 8:12 PM UTC


NEW YORK, Aug. 19, 2024?In a significant development for the biopharmaceutical landscape, Titan Pharmaceuticals, Inc. (NASDAQ: TTNP) has formally announced a merger with KE Sdn. Bhd. This strategic move aims to enhance Titan s capabilities in developing proprietary therapeutics through a reverse merger transaction that could reshape the future of the company.
The Me...

Titan Pharmaceuticals Inc

TTNP's Lackluster Performance Leaves Investors Disappointed during Q1 Earnings Report

Investors in Titan Pharmaceuticals Inc received some positive news recently as the company announced it has regained compliance with the NASDAQ listing criteria. This development indicates that Titan meets all necessary requirements for continued listing on The Nasdaq Capital Market, alleviating concerns of potential delisting.
The company has been working towards improving its financial standing, with the first quarter of 2024 earnings season showing a decrease in loss per share compared to the previous year. Additionally, Titan reported a net loss of $-1.060 million, a significant improvement from the deficit of $-1.675 million in the same quarter a year ago.

Titan Pharmaceuticals Inc

2. Titan Pharmaceuticals Inc. Sees Major Revenue Plunge in Fourth Quarter of 2023

r/>Titan Pharmaceuticals Inc. (NASDAQ: TTNP) recently released its financial results for the fourth quarter of 2023, revealing a significant decline in revenue and a substantial increase in per share shortfall. However, the company has successfully regained compliance with the minimum $1.00 bid price requirement, bringing some relief to investors and alleviating concerns about potential delisting.
1. Financial Results:
a. Revenue: In the fourth quarter of 2023, Titan Pharmaceuticals Inc. experienced a staggering decline in revenue of -81.667%, falling to $0.02 million from the comparable reporting season a year before. Sequentially, revenue tumbled by -98.733% from $1.74 million in the previous reporting season. This significant decrease paints a bleak picture for the company's financial performance.

Management Announcement

Titan Pharmaceuticals Regains NASDAQ Compliance and Works Towards Enhanced Financial Performance

Published Thu, Jan 25 2024 9:29 PM UTC

Titan Pharmaceuticals Regains Compliance With NASDAQ Listing Criteria and Works Toward Improved ROI
Titan Pharmaceuticals, Inc. (NASDAQ: TTNP) has recently announced that it has successfully regained compliance with the minimum $1.00 bid price requirement, marking a positive development for the company. In a letter dated January 24, 2024, The Nasdaq Stock Market LLC con...










Help

About us

Advertise

CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research. 
   Copyright © 2025 CSIMarket, Inc. All rights reserved.

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com